3-Isopropylamino-chinolin | 78641-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-Isopropylamino-chinolin
• 英文别名: N-(propan-2-yl)quinolin-3-amine；N-propan-2-ylquinolin-3-amine
• CAS: 78641-29-9
• 化学式: C₁₂H₁₄N₂
• mdl: MFCD12121471
• 分子量: 186.257
• InChiKey: PVIQJPNURFLZSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-Quinolinyl(1-methylethylidene)amine 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 0.25h， 生成 3-Isopropylamino-chinolin
  参考文献：
  名称：

  3-氨基喹啉的合成及反应行为

  摘要：

  3-氨基喹啉 (3) 由 3-溴喹啉与氨反应以良好的收率生产。3 的取代是通过卤代烷对其钠盐的作用或通过与芳香族和脂肪族酮的还原性烷基化来实现的。苯乙酮曼尼希碱被 3 胺化。3 不与甲基乙烯基酮和丙烯腈形成任何加成产物。添加到苯基缩水甘油酸衍生物导致形成相应的 β-苯基-异丝氨酸衍生物。

  DOI：

  10.1002/ardp.19813140515

文献信息

• Spiropyrrolidine derived antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11339170B1

  公开（公告）日：2022-05-24

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

  本发明揭示了式（I）的化合物及其药学上可接受的盐：可抑制冠状病毒复制活性。本发明还涉及包含式（I）的化合物或其药学上可接受的盐的制药组合物，以及治疗或预防受冠状病毒感染的患者的方法，包括向患者施用式（I）的化合物或其药学上可接受的盐的治疗有效量。
• ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS
  申请人：Glinka Tomasz

  公开号：US20080076741A1

  公开（公告）日：2008-03-27

  Disclosed herein are Efflux Pump Inhibitor (EPI) compounds that can be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. It is demonstrated that the EPIs can be used to increase the potency, decrease bacterial resistance and development of bacterial resistance, and increase killing effectivness of tigecycline. Also disclosed are methods of treatment and pharmaceutical compositions for co-administering tigecylcine with an EPI.

  本文公开了外排泵抑制剂（EPI）化合物，可以与抗微生物药物联合使用，用于治疗由耐药病原体引起的感染。这些EPI化合物是软药物，具有降低组织积累的倾向。证明EPI可以用于增加替加环素的效力，降低细菌耐药性和细菌耐药性的发展，并增加杀菌效果。同时，还公开了联合使用替加环素和EPI的治疗方法和制药组合物。
• Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
  申请人：CALGENT BIOTECHNOLOGY CO., LTD.

  公开号：US10745350B2

  公开（公告）日：2020-08-18

  The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.

  本发明涉及用于阻断疾病中泛素化-蛋白酶体系统的低细胞毒性新化合物。因此，这些化合物可用于治疗各种疾病，包括但不限于癌症、神经退行性疾病、炎症性疾病、自身免疫性疾病和代谢性疾病。
• Complex base-induced generation of 3,4-dehydroquinoline: a new access to quinoline derivatives
  作者：Stéphanie Blanchard、Gérald Guillaumet、Paul Caubère

  DOI：10.1016/s0040-4039(01)01339-9

  日期：2001.10

  3,4-Dehydroquinoline was easily generated from 3-bromoquinoline and a complex base NaNH2-tBuONa. Nucleophilic condensation of amines and thiolates were performed in good yields. (C) 2001 Elsevier Science Ltd. All rights reserved.
• SCHOENEN B.; ZYMALKOWSKI F., ARCH. PHARM., 1981, 314, NO 5, 464-470
  作者：SCHOENEN B.、 ZYMALKOWSKI F.

  DOI：——

  日期：——